JMP Securities Reiterates Market Outperform Rating for Kura Oncology (NASDAQ:KURA)

Kura Oncology (NASDAQ:KURA)‘s stock had its “market outperform” rating reissued by research analysts at JMP Securities in a note issued to investors on Monday, Benzinga reports. They presently have a $32.00 price objective on the stock. JMP Securities’ price target indicates a potential upside of 52.74% from the stock’s current price.

Several other equities analysts have also issued reports on KURA. Wedbush reaffirmed an “outperform” rating and issued a $37.00 price target on shares of Kura Oncology in a report on Friday. StockNews.com downgraded shares of Kura Oncology from a “hold” rating to a “sell” rating in a research report on Monday, April 15th. Finally, HC Wainwright reissued a “buy” rating and set a $32.00 target price on shares of Kura Oncology in a research note on Friday. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $28.28.

Kura Oncology Stock Performance

Shares of NASDAQ KURA traded up $0.32 during midday trading on Monday, hitting $20.95. 194,269 shares of the stock traded hands, compared to its average volume of 1,273,084. The firm has a 50-day moving average of $20.66 and a two-hundred day moving average of $16.04. The firm has a market capitalization of $1.60 billion, a P/E ratio of -9.65 and a beta of 0.89. The company has a debt-to-equity ratio of 0.02, a quick ratio of 16.67 and a current ratio of 16.67. Kura Oncology has a one year low of $7.41 and a one year high of $24.17.

Kura Oncology (NASDAQ:KURA) last issued its quarterly earnings data on Thursday, May 2nd. The company reported ($0.59) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.03). During the same quarter in the previous year, the firm posted ($0.50) earnings per share. The business’s revenue was up .0% on a year-over-year basis. On average, equities analysts forecast that Kura Oncology will post -2.35 EPS for the current fiscal year.

Hedge Funds Weigh In On Kura Oncology

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. BVF Inc. IL increased its stake in Kura Oncology by 9.5% in the fourth quarter. BVF Inc. IL now owns 7,373,228 shares of the company’s stock valued at $106,027,000 after purchasing an additional 642,245 shares during the period. Deerfield Management Company L.P. Series C increased its position in Kura Oncology by 35.1% during the third quarter. Deerfield Management Company L.P. Series C now owns 4,374,044 shares of the company’s stock worth $39,891,000 after purchasing an additional 1,136,044 shares during the last quarter. Vanguard Group Inc. increased its position in shares of Kura Oncology by 7.5% in the third quarter. Vanguard Group Inc. now owns 3,924,448 shares of the company’s stock worth $35,791,000 after acquiring an additional 275,173 shares in the last quarter. Armistice Capital LLC boosted its stake in shares of Kura Oncology by 5.3% in the third quarter. Armistice Capital LLC now owns 2,236,000 shares of the company’s stock valued at $20,392,000 after purchasing an additional 112,000 shares during the period. Finally, Dimensional Fund Advisors LP boosted its stake in Kura Oncology by 10.9% during the 4th quarter. Dimensional Fund Advisors LP now owns 2,001,754 shares of the company’s stock valued at $28,785,000 after acquiring an additional 197,530 shares during the last quarter.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.